MedPath

Study of the Effects of PRALIA 60 mg Subcutaneous Injection Syringe on the Physical Functions, etc. of Rheumatoid Arthritis Patients

Not Applicable
Recruiting
Conditions
Rheumatoid arthritis
Registration Number
JPRN-jRCT2031210189
Lead Sponsor
Matsuoka Yomei
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
960
Inclusion Criteria

Initial examination, diagnosis of rheumatoid arthritis, receipt of a prescription for a DMARD (including biologics) during the enrollment period at the Kyoto University Hospital Rheumatic Disease Center

Exclusion Criteria

History of a bone or joint surgical procedure, receipt of a prescription for a RANKL inhibitor prior to the day of the initial examination at the Kyoto University Hospital Rheumatic Disease Center

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath